Background: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. Summary: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). Key Messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is moderated by dementia subtype. For memantine the effect is smaller.

Keywords:
Acetylcholinesterase inhibitor, Memantine, Alzheimer disease, Vascular dementia, Systematic review, Meta-analysis
1.
Terry AV Jr, Buccafusco JJ: The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821–827.
2.
Cacabelos R, Takeda M, Winblad B: The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry 1999; 14: 3–47.
3.
van de Glind EMM, van Enst WA, van Munster BC, Olde Rikkert MGM, Scheltens P, Scholten RJPM, Hooft L: Pharmacological treatment of dementia: a scoping review of systematic reviews. Dement Geriatr Cogn Disord 2013; 36: 211–228.
4.
Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ: Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20–27.
5.
Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; 1:CD005593.
6.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
7.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.
8.
Panisset M, Roudier M, Saxton J, Boiler F: Severe Impairment Battery. A neuropsychological test for severely demented patients. Arch Neurol 1994; 51: 41–45.
9.
Tan C-C, Yu J-T, Wang H-F, Tan M-S, Meng X-F, Wang C, Jiang T, Zhu X-C, Tan L: Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 2014; 41: 615–631.
10.
Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M: A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis 2013; 35: 349–361.
11.
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379–397.
12.
Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, 2011, 2013.
13.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
14.
Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
15.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
16.
R Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2014.
17.
Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1–48.
18.
Knapp G, Hartung J: Improved tests for a random effects meta-regression with a single covariate. Stat Med 2003; 22: 2693–2710.
19.
Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV: Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15: 794–802.
20.
Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54: 407–411.
21.
Birks J, McGuinness B, Craig D: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013; 5:CD004744.
22.
Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2006; 1:CD001190.
23.
Perera G, Khondoker M, Broadbent M, Breen G, Stewart R: Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in London. PLoS One 2014; 9:e109484.
24.
Ballard C, O’Brien J, Morris C, Barber R, Swann A, Neill D, McKeith I: The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 499–503.
25.
Knapp M, Chua K-C, Broadbent M, Chang C-K, Fernandez J-L, Milea D, Romeo R, Lovestone S, Spencer M, Thompson G: Predictors of care home and hospital admissions and their costs for older people with Alzheimer’s disease: findings from a large London case register. BMJ Open 2016; 6:e013591.
26.
Franco-Marina F, García-González JJ, Wagner-Echeagaray F, Gallo J, Ugalde O, Sánchez-García S, Espinel-Bermúdez C, Juárez-Cedillo T, Rodríguez MÁV, García-Peña C: The Mini-Mental State Examination revisited: ceiling and floor effects after score adjustment for educational level in an aging Mexican population. Int Psychogeriatr 2010; 22: 72–81.
27.
Dong Y, Sharma VK, Chan BP-L, Venketasubramanian N, Teoh HL, Seet RCS, Tanicala S, Chan YH, Chen C: The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010; 299: 15–18.
28.
Osher JE, Wicklund AH, Rademaker A, Johnson N, Weintraub S: The Mini-Mental State Examination in behavioral variant frontotemporal dementia and primary progressive aphasia. Am J Alzheimers Dis Other Demen 2007; 22: 468–473.
29.
Frölich L, Ashwood T, Nilsson J, Eckerwall G; Sirocco Investigators: Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: a phase IIb dose-finding study. J Alzheimers Dis 2011; 24: 363–374.
30.
Gault LM, Ritchie CW, Robieson WZ, Pritchett Y, Othman AA, Lenz RA: A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. Alzheimers Dement 2015; 1: 81–90.
31.
Geldmacher DS, Perdomo C, Pratt R: Effect of donepezil treatment on visual attention/exploration tasks in patients with mild to moderately severe Alzheimer’s disease: results of a pilot study. Neurobiol Aging 2000; 21:S169.
32.
Marek GJ, Katz DA, Meier A, Greco N 4th, Zhang W, Liu W, Lenz RA: Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer’s disease. Alzheimers Dement 2014; 10(suppl):S364–S373.
33.
Peng DT, Xu XH, Wang LN: Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease. Chin J Clin Rehabil 2005; 9: 170–172.
34.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021–1031.
35.
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O’Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med 2007; 357: 1382–1392.
36.
Moraes W, Poyares D, Sukys-Claudino L, Guilleminault C, Tufik S: Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest 2008; 133: 677–683.
37.
Solé-Padullés C, Bartrés-Faz D, Lladó A, Bosch B, Peña-Gómez C, Castellví M, Rami L, Bargalló N, Sánchez-Valle R, Molinuevo JL: Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer’s disease. J Clin Psychopharmacol 2013; 33: 199–205.
38.
Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA: A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimers Dis 2014; 42: 959–971.
39.
Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459–469.
40.
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–244.
41.
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–620.
42.
Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S: Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30: 131–146.
43.
Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299–313.
44.
Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, Li F, Shi L, Doody RS: Efficacy and safety of donepezil in Chinese patients with severe Alzheimer’s disease: a randomized controlled trial. J Alzheimers Dis 2017; 56: 1495–1504.
45.
Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P: SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011; 26: 536–544.
46.
Mazza M, Capuano A, Bria P, Mazza S: Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981–985.
47.
Gault LM, Lenz RA, Ritchie CW, Meier A, Othman AA, Tang Q, Berry S, Pritchett Y, Robieson WZ: ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther 2016; 8: 44.
48.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT; Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136–145.
49.
Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S; Donepezil “402” Study Group: Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–1856.
50.
Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM: Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003; 11: 169–177.
51.
Maher-Edwards G, Watson C, Ascher J, Barnett C, Boswell D, Davies J, Fernandez M, Kurz A, Zanetti O, Safirstein B, Schronen JP, Zvartau-Hind M, Gold M: Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer’s disease. Alzheimers Dement 2015; 1: 23–36.
52.
dos Santos Moraes WA, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S: The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006; 29: 199–205.
53.
Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, Jarisson-Blixt C, Haglund A; Severe Alzheimer’s Disease Study Group: Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057–1065.
54.
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–495.
55.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; “312” Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–488.
56.
Bentham P, Gray R, Raftery J, Hills R, Sellwood E, Courtney C, Farrell D, Hardyman W, Crome P, Edwards S, Lendon C, Lynch L; AD2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–2115.
57.
Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590–1599.
58.
Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R; Donepezil 307 Vascular Dementia Study Group: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323–2330.
59.
Román GC, Salloway S, Black SE, Royall DR, DeCarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H: Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010; 41: 1213–1221.
60.
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; Donepezil 308 Study Group: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479–486.
61.
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS: Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7: 310–318.
62.
Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708–712.
63.
Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T: Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934–939.
64.
Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19: 1–8.
65.
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML: Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230–1238.
66.
Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015; 7: 4.
67.
Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41–52.
68.
Wilkinson D, Murray J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001; 16: 852–857.
69.
Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Långström B, Nordberg A: PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 2008; 29: 1204–1217.
70.
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589–595.
71.
Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators: Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174: 1099–1105.
72.
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–2276.
73.
Brodaty H, Corey-Bloom J, Potocnik FCV, Truyen L, Gold M, Damaraju CRV: Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20: 120–132.
74.
Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–2268.
75.
Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445–1449.
76.
Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, Teipel SJ: Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. Eur Arch Psych Clin Neurosci 2012; 262: 341–350.
77.
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM: Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat 2014; 10: 391–401.
78.
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–1290.
79.
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C; GAL-INT-26 Study Group: Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69: 448–458.
80.
Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY: Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 2008; 38: 937–945.
81.
Koch G, Di Lorenzo F, Bonni S, Giacobbe V, Bozzali M, Caltagirone C, Martorana A: Dopaminergic modulation of cortical plasticity in Alzheimer’s disease patients. Neuropsychopharmacology 2014; 39: 2654–2661.
82.
Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A: Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007; 27: 484–487.
83.
Iranmanesh F, Vakilian A, Gadari F, Syadi A, Mehrabian M, Moradi M, Raesy E: Piracetam, rivastigmine and their joint consumption effects on MMSE score status in patients with Alzheimer’s disease. IJPT 2012; 11: 60–63.
84.
Agid Y, Dubois B, Anand R, Gharabawi G; International Rivastigmine Investigators: Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 1998; 59: 837–845.
85.
Forette F, Anand R, Gharabawi G: A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 1999; 6: 423–429.
86.
Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456–467.
87.
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–638.
88.
Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65.
89.
Feldman HH, Lane R: Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056–1063.
90.
Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO: A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 51–56.
91.
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten ECW, van der Flier WM, Hsu C, Wu S, Lane R: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008; 24: 2561–2574.
92.
Mok V, Wong A, Ho S, Leung T, Lam WWM, Wong KS: Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatr Dis Treat 2007; 3: 943–948.
93.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–2518.
94.
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G: Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One 2012; 7:e35185.
95.
Bakchine S, Loft H: Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008; 13: 97–107.
96.
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S: Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704–715.
97.
Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S: Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol 2013; 33: 636–642.
98.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–1341.
99.
Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, Rosen A, O’Hara R, Fairchild JK, Spielman D, Yesavage JA: MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. J Alzheimers Dis 2011; 26(suppl 3): 331–336.
100.
Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P: Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial. J Alzheimers Dis 2012; 29: 459–469.
101.
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–1839.
102.
Wilcock G, Möbius HJ, Stöffler A; MMM 500 Group: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297–305.
103.
Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A: Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord 2009; 24: 1217–1221.
104.
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E: Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–618.
105.
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL: Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013; 12: 149–156.
106.
Vercelletto M, Boutoleau-Bretonnière C, Volteau C, Puel M, Auriacombe S, Sarazin M, Michel BF, Couratier P, Thomas-Antérion C, Verpillat P, Gabelle A, Golfier V, Cerato E, Lacomblez L; French Research Network on Frontotemporal Dementia: Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011; 23: 749–759.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.